dabrafenib capsules
for oral use Initial U.S. Approval: 2013

As specified in the prescribing information, dabrafenib capsules is indicated for the treatment of melanoma. TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. BRAF V600E Mutation-Positive Unresectable or Metastatic Melanoma, BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma, Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma, BRAF V600E Mutation-Positive Metastatic NSCLC, BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer, BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Facts about dabrafenib capsules

Approval Date: 2013
Proprietary Name: TAFINLAR (dabrafenib) capsules
Active Ingredient(s): dabrafenib
FDA-approved use: melanoma
Dosage Form: Capsules: 50 mg, 75 mg
Medicine Approved By: US FDA
Manufacturer: Novartis Pharmaceuticals Corporation
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)

Access the best support services globally

If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication.  Our professional will provide you with a step-by-step guide on how to legally and safely import “dabrafenib capsules” based on the information you provide.

Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.